IN SILICO INHIBITION OF UREASE AND CagA ENZYMES AS TARGETS AGAINST HELICOBACTER PYLORI: AN OVERVIEW ON CAPES 2022 DATABASE
DOI:
https://doi.org/10.25110/arqsaude.v28i1.2024-10831Palavras-chave:
CAPES, Helicobacter Pylori, In silico method, Inhibition of enzymesResumo
The proliferation, adaptive capability, and action of the Helicobacter pylori bacterium in the human stomach make it a worldwide public health issue. This bacterium is associated with gastrointestinal diseases such as stomach cancer. Adding to this challenge is the emergence of multi-drug-resistant and pan-drug-resistant pathogens among gram-negative bacteria, a category to which Helicobacter pylori belongs, making the elimination of this microorganism a daunting task. Therefore, there is an urgent need for the development of new treatment strategies to address this issue, and one potential way is the in silico method, specifically Computer-Aided Drug Design (CADD), which suggests new starting points in the search for innovative therapies and can be combined with traditional research methods (in vitro, in vivo, and ex-vivo). In this context, this review, utilizing data from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) database, provides an overview of the various proposals discussed in 2022 that focus on the inhibition of proteins favorable to the colonization, virulence, and pathogenicity of H. pylori using in silico methods. Thus, several articles were inspected in the CAPES database. With a focus on molecular docking and/or molecular dynamics, pharmacokinetics, drug-like characteristics, and toxicity, 15 articles were identified that indicated the most studied enzymes in 2022 were urease and CagA. Furthermore, it was observed that the nature of the compounds used in inhibition was diverse - essential oils, flavonoids, pyrazolines, benzimidazoles, tetrahydropyrimidines, and benzothiazoles. All of these compounds were found to have the potential to be anti-urease and/or anti-CagA agents.
Referências
ADEOYE, M. D. et al. Biological evaluation of selected metronidazole derivatives as anti-nitroreductase via in silico approach. Eclética Química Journal, v. 47, n. 4, p. 27-36, 2022.
AKOPYANTS, N. S. et al. Analyses of the cag pathogenicity island of Helicobacter pylori: H. pylori pathogenicity island. Molecular Microbiology, v. 28, n. 1, p. 37-53, 2002.
ALOMAR, H. A. et al. GC-MS Profiling, Anti-Helicobacter pylori, and Anti-Inflammatory Activities of Three Apiaceous Fruits’ Essential Oils. Plants, v. 11, n. 19, p. 2617, 2022.
AL TAWALBEH, D. et al. In Silico and In Vitro Investigation of Anti Helicobacter Activity of Selected Phytochemicals. Journal of Pharmacy And Bioallied Sciences, v. 14, n. 3, p. 132, 2022.
AHANGARZADEH, N. et al. Design, synthesis, and in silico studies of tetrahydropyrimidine analogs as urease enzyme inhibitors. Archiv der Pharmazie, v. 355, n. 10, p. 2200158, 2022.
BACKERT, S.; TEGTMEYER, N.; SELBACH, M. The Versatility of Helicobacter pylori CagA Effector Protein Functions: The Master Key Hypothesis: The Versatility of H. pylori CagA. Helicobacter, v. 15, n. 3, p. 163–176, 2010.
EATON, K. A. et al. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets. Infection and Immunity, v. 59, n. 7, p. 2470-2475, 1991.
ELKOUSY, R. H. et al. GC/MS analysis and potential synergistic effect of mandarin and marjoram oils on Helicobacter pylori. Journal of Enzyme Inhibition and Medicinal Chemistry, v. 37, n. 1, p. 1610-1619, 2022.
EJAZ, S. et al. Chitosan-curcumin complexation to develop functionalized nanosystems with enhanced antimicrobial activity against hetero-resistant gastric pathogen. International Journal of Biological Macromolecules, v. 204, p. 540-554, 2022.
FIORI-DUARTE, A. T. et al. In silico design and in vitro assessment of anti-Helicobacter pylori compounds as potential small-molecule arginase inhibitors. Molecular Diversity, v. 26, n. 6, p. 3365-3378, 2022.
GRAHAM, D. Y. Helicobacter pylori Update: Gastric Cancer, Reliable Therapy, and Possible Benefits. Gastroenterology, v. 148, n. 4, p. 719- 731.e3, 2015.
HATAKEYAMA, M. Helicobacter pylori CagA and Gastric Cancer: A Paradigm for Hit-and-Run Carcinogenesis. Cell Host & Microbe, v. 15, n. 3, p. 306-316, 2014.
HE, S. et al. Targeting Cytotoxin-Associated Antigen A, a Virulent Factor of Helicobacter pylori-Associated Gastric Cancer: Structure-Based In Silico Screening of Natural Compounds. Molecules, v. 27, n. 3, p. 732, 2022.
HIGASHI, H. et al. SHP-2 Tyrosine Phosphatase as an Intracellular Target of Helicobacter pylori CagA Protein. Science, v. 295, n. 5555, p. 683–686, 2002.
HOOI, J. K. Y. et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology, v. 153, n. 2, p. 420–429, 2017.
IBRAHIM, K. A. et al. Aspartate α-decarboxylase a new therapeutic target in the fight against Helicobacter pylori infection. Frontiers in Microbiology, v. 13, p. 1019666, 2022.
KARAISKOS, I. et al. The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. Frontiers in Public Health, v. 7, p. 151, 2019.
MALFERTHEINER, P.; SELGRAD, M.; BORNSCHEIN, J. Helicobacter pylori: clinical management. Current Opinion in Gastroenterology, v. 28, n. 6, p. 608–614, 2012.
MALFERTHEINER, P. et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut, v. 66, n. 1, p. 6-30, 2017.
MEHMOOD, R. et al. Synthesis and Evaluation of 1,3,5-Triaryl-2-Pyrazoline Derivatives as Potent Dual Inhibitors of Urease and α-Glucosidase Together with Their Cytotoxic, Molecular Modeling and Drug-Likeness Studies. ACS Omega, v. 7, n. 4, p. 3775-3795, 2022.
MOHAMMED, S. O. et al. Expression, Purification, and Comparative Inhibition of Helicobacter pylori Urease by Regio-Selectively Alkylated Benzimidazole 2-Thione Derivatives. Molecules, v. 27, n. 3, p. 865, 27 jan. 2022.
ODENBREIT, S. et al. Translocation of Helicobacter pylori CagA into Gastric Epithelial Cells by Type IV Secretion. Science, v. 287, n. 5457, p. 1497-1500, 2000.
OLIVERA-SEVERO, D. et al. A New Role for Helicobacter pylori Urease: Contributions to Angiogenesis. Frontiers in Microbiology, v. 8, p. 1883, 2017.
PEREIRA, C. et al. 2-(Pyridin-4yl) benzothiazole and Its Benzimidazole-Analogue: Biophysical and in silico Studies on Their Interaction with Urease and in vitro Anti-Helicobacter pylori Activities. Journal of the Brazilian Chemical Society, 2022.
PEREZ-PEREZ, G. I.; BLASER, M. J. Campylobacter and Helicobacter. In: BARON, S. (Ed.). Medical Microbiology. 4th. ed. Galveston (TX): University of Texas Medical Branch at Galveston, 1996.
QUY, P. T. et al. In silico study on inhibitability of flavonoidal derivatives against Helicobacter pylori and their pharmacological potentiality. Vietnam Journal of Chemistry, v. 60, n. 4, p. 435-450, 2022.
RU, Z. et al. Immmunoinformatics‐based design of a multi‐epitope vaccine with CTLA‐4 extracellular domain to combat Helicobacter pylori. The FASEB Journal, v. 36, n. 4, 2022.
WEEKS, D. L.; SACHS, G. Sites of pH regulation of the urea channel of Helicobacter pylori. Molecular Microbiology, v. 40, n. 6, p. 1249–1259, 2001.
World Gastroenterology Organization (WGO). Available at: https://www.worldgastroenterology.org. Acesso em: 4 fev. 2023.
ZHOU, G. et al. Insight into the Potential of Meehania fargesii var. Radicans against Hp‐Induced Gastric Carcinoma Based on Phytochemical and Molecular Docking Studies. Chemistry & Biodiversity, v. 19, n. 7, p. e202200383, 2022.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2024 Arquivos de Ciências da Saúde da UNIPAR
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Os Direitos Autorais para artigos publicados são de direito da revista. Em virtude da aparecerem nesta revista de acesso público, os artigos são de uso gratuito, com Creative Commons Attribution 4.0 International License.
A revista se reserva o direito de efetuar, nos originais, alterações de ordem normativa, ortográfica e gramatical, com vistas a manter o padrão culto da língua e a credibilidade do veículo. Respeitará, no entanto, o estilo de escrever dos autores.
Alterações, correções ou sugestões de ordem conceitual serão encaminhadas aos autores, quando necessário. Nesses casos, os artigos, depois de adequados, deverão ser submetidos a nova apreciação.
As opiniões emitidas pelos autores dos artigos são de sua exclusiva responsabilidade.
